INVO Fertility (IVF) Registration Filing summary

Company overview and business model

• Operates as a life science portfolio company with a hub-and-spoke model, focusing on oncology, autoimmune diseases, and fertility.

• Acquires, develops, and partners assets through centralized management and lean subsidiaries, combining clinical-stage therapeutics with commercial revenues.

• Principal operations include Naya Therapeutics (oncology/autoimmune) and Naya Women's Health (fertility clinics and INVOcell device).

• Recent expansion includes the acquisition of Legacy NAYA, integrating clinical-stage oncology assets with commercial fertility business.

Financial performance and metrics

• Accumulated net loss of $63.5 million from inception through September 30, 2024.

• Current cash position is insufficient to fund operations for the next 12 months without additional financing.

• Ongoing net operating losses and limited working capital highlight a high-risk financial profile.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used as set forth in the applicable prospectus supplement.